Prior to its acquisition, Seagen (formerly Seattle Genetics) operated as a leading commercial-stage biotechnology enterprise with a workforce numbering approximately 3,000 dedicated professional employees. Its organizational footprint expanded massively when Pfizer completed a landmark $43 billion acquisition of Seagen, integrating its specialized antibody-drug conjugate (ADC) oncology infrastructure, clinical research facilities, and global workforce into Pfizer's broader multi-national biopharmaceutical operations.